Topic: Pfizer Liability

Robert F. Kennedy Jr. explains that pharmaceutical companies like Pfizer and Moderna seek to add COVID-19 vaccines to the childhood immunization schedule to gain permanent liability protection. Under the PREP Act and CARES Act, emergency use authorization provides temporary immunity, but a formal recommendation for children shields manufacturers from lawsuits across all age groups.

The push to add COVID-19 vaccines to the childhood immunization schedule is linked to shifting legal liability from the manufacturers to the National Vaccine Injury Compensation Program. This transition would protect companies like Pfizer once Emergency Use Authorizations expire.

World Bank President David Malpass identifies legal indemnification as a primary barrier to vaccine distribution in developing nations. He notes that Pfizer is hesitant to enter markets where a liability shield is not established, unlike in the United States and European Union. The discussion highlights the standoff between pharmaceutical profit protection and global health mandates.

Robert F. Kennedy Jr. explains the historical origins of vaccine manufacturer liability protection during an interview with Tucker Carlson. The 1986 National Childhood Vaccine Injury Act was passed after insurance companies refused to cover manufacturers due to high injury rates from the DTP vaccine. The legislation established that vaccines are "unavoidably unsafe," granting companies blanket immunity from lawsuits.

John C. Dvorak predicts that the government may eventually pull the plug on vaccine liability protections once the scale of adverse events becomes undeniable. He suggests that Moderna might become the "Lehman Brothers" of the pharmaceutical industry, serving as a scapegoat for mRNA-related issues. The hosts argue that the current system of no liability is a "feature, not a bug" for Big Pharma.

The FDA's full approval of the Pfizer-BioNTech vaccine, rebranded as Comirnaty, has created confusion regarding legal liability. While Comirnaty is approved, the existing stock of Pfizer vaccines remains under Emergency Use Authorization (EUA), which maintains a liability shield for the manufacturer. Critics argue the approval process bypassed traditional advisory committee discussions to expedite mandates.

The hosts explore the legal implications of companies requiring employees to receive experimental vaccines. They discuss Pfizer's request for full FDA approval, which could lead to more government and private sector mandates. The segment highlights Virginia Wesleyan University and other colleges already requiring vaccination records for students.

Pfizer is accused of demanding extreme concessions from national governments in exchange for vaccine supplies, including immunity from negligence lawsuits. In Argentina, the company reportedly requested sovereign assets—such as bank reserves, military bases, and embassy buildings—as collateral. This aggressive business posture is contrasted with the situation in Israel, where Pfizer secured an exclusive deal to use the entire population as a data set.

Andrew Yang proposed offering $1,500 to Americans who receive the COVID-19 vaccine to encourage uptake and return to normalcy. Public concern remains regarding the legal immunity granted to vaccine manufacturers like Pfizer and Moderna under federal law. Questions are raised about the long-term effects of mRNA technology and the lack of traditional liability for potential injuries.

The pharmaceutical industry is heavily promoting vaccines as a high-profit, low-liability business sector. A recent Supreme Court ruling protected vaccine manufacturers from being sued for damages. The hosts argue that mainstream media outlets, which are heavily funded by pharmaceutical advertising, are incapable of reporting objectively on the risks or corruption within the industry.